Top-Rated StocksTop-Rated iRhythm Technologies Stock Price, News & Analysis (NASDAQ:IRTC) $86.87 +1.92 (+2.26%) (As of 12/7/2023 ET) Add Compare Share Share Today's Range$84.72▼$87.8050-Day Range$72.43▼$94.2652-Week Range$70.24▼$140.23Volume269,706 shsAverage Volume360,896 shsMarket Capitalization$2.66 billionP/E RatioN/ADividend YieldN/APrice Target$131.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media iRhythm Technologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside51.2% Upside$131.33 Price TargetShort InterestHealthy6.04% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.25) to ($2.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.68 out of 5 starsMedical Sector790th out of 960 stocksMedical Devices Industry19th out of 24 stocks 3.4 Analyst's Opinion Consensus RatingiRhythm Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $131.33, iRhythm Technologies has a forecasted upside of 51.2% from its current price of $86.87.Amount of Analyst CoverageiRhythm Technologies has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.04% of the outstanding shares of iRhythm Technologies have been sold short.Short Interest Ratio / Days to CoveriRhythm Technologies has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in iRhythm Technologies has recently decreased by 18.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldiRhythm Technologies does not currently pay a dividend.Dividend GrowthiRhythm Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IRTC. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows7 people have added iRhythm Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iRhythm Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.43% of the stock of iRhythm Technologies is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for iRhythm Technologies are expected to grow in the coming year, from ($3.25) to ($2.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iRhythm Technologies is -25.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iRhythm Technologies is -25.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiRhythm Technologies has a P/B Ratio of 10.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About iRhythm Technologies Stock (NASDAQ:IRTC)iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.Read More IRTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRTC Stock News HeadlinesNovember 30, 2023 | benzinga.comiRhythm Technologies Stock (NASDAQ:IRTC) Dividends: History, Yield and DatesNovember 13, 2023 | finance.yahoo.comNew Research Presented at American Heart Association’s 2023 Scientific Sessions Demonstrates Performance of Continuous Monitoring ECG Data for Improved Prediction of Heart Failure HospitalizationDecember 8, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 4, 2023 | markets.businessinsider.comPositive Outlook for Irhythm Technologies: Resolving Regulatory Issues, Revenue Growth and Future Prospects Despite Comp Group Multiple CompressionNovember 3, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About iRhythm TechnologiesNovember 3, 2023 | finance.yahoo.comEven after rising 8.2% this past week, iRhythm Technologies (NASDAQ:IRTC) shareholders are still down 66% over the past three yearsNovember 3, 2023 | finance.yahoo.comQ3 2023 iRhythm Technologies Inc Earnings CallNovember 3, 2023 | finance.yahoo.comiRhythm Technologies, Inc. (NASDAQ:IRTC) Q3 2023 Earnings Call TranscriptDecember 8, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 2, 2023 | finance.yahoo.comiRhythm Technologies Announces Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comiRhythm Technologies Inc (IRTC) Reports 20% Revenue Growth in Q3 2023November 2, 2023 | seekingalpha.comiRhythm Technologies, Inc. 2023 Q3 - Results - Earnings Call PresentationOctober 27, 2023 | finance.yahoo.comDown -23.87% in 4 Weeks, Here's Why iRhythm Technologies (IRTC) Looks Ripe for a TurnaroundOctober 26, 2023 | finance.yahoo.comIRhythm Technologies (IRTC) Expected to Beat Earnings Estimates: Should You Buy?October 19, 2023 | reuters.comColumn: First-to-file shareholder rebuffed in bid to appeal dismissal of iRhythm class actionOctober 19, 2023 | finance.yahoo.comiRhythm Technologies to Report Third Quarter 2023 Financial Results on November 2, 2023October 13, 2023 | seekingalpha.comiRhythm: Implied Expectations Appear Warranted, High Risk Priced In At Current MultiplesOctober 11, 2023 | markets.businessinsider.comBuy Rating Maintained for Irhythm Technologies Amidst Anticipated Q4 Surge Post-ZioMonitor Product LaunchSeptember 26, 2023 | finance.yahoo.comiRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac MonitorSeptember 22, 2023 | finance.yahoo.comUnveiling iRhythm Technologies (IRTC)'s Value: Is It Really Priced Right? A Comprehensive GuideSeptember 20, 2023 | finance.yahoo.comiRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Could Be 33% Below Their Intrinsic Value EstimateAugust 29, 2023 | finance.yahoo.comiRhythm Technologies to Participate in Two Investor Conferences in SeptemberAugust 29, 2023 | nasdaq.comCanaccord Genuity Maintains iRhythm Technologies (IRTC) Buy RecommendationAugust 9, 2023 | markets.businessinsider.comTruist Financial Remains a Buy on Irhythm Technologies (IRTC)August 7, 2023 | markets.businessinsider.comIRhythm Technologies' Cost Efficiency And Potential Entry Into The Japanese Market Earn Analyst ApplaudAugust 5, 2023 | markets.businessinsider.comStrong Zio AT Business Growth Propels iRhythm's Q2 Revenue Surge, Analysts Say Warning Letter ManageableAugust 4, 2023 | finance.yahoo.comIs iRhythm Technologies, Inc. (NASDAQ:IRTC) Potentially Undervalued?See More Headlines Receive IRTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iRhythm Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IRTC CUSIPN/A CIK1388658 Webwww.irhythmtech.com Phone(415) 632-5700FaxN/AEmployees1,793Year FoundedN/APrice Target and Rating Average Stock Price Target$131.33 High Stock Price Target$165.00 Low Stock Price Target$100.00 Potential Upside/Downside+51.2%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,150,000.00 Net Margins-22.19% Pretax Margin-22.07% Return on Equity-46.35% Return on Assets-24.13% Debt Debt-to-Equity Ratio0.16 Current Ratio2.29 Quick Ratio2.16 Sales & Book Value Annual Sales$410.92 million Price / Sales6.48 Cash FlowN/A Price / Cash FlowN/A Book Value$7.96 per share Price / Book10.91Miscellaneous Outstanding Shares30,650,000Free Float30,519,000Market Cap$2.66 billion OptionableOptionable Beta1.31 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Quentin S. Blackford (Age 44)President, CEO & Director Comp: $2.15MMr. Brice Bobzien CPA (Age 44)Chief Financial Officer Comp: $685.12kDr. Minang P. Turakhia M.D. (Age 49)M.S., Chief Medical & Scientific Officer and Executive VP of Product Innovation Comp: $1MMr. Patrick Michael Murphy J.D. (Age 44)Chief Business & Legal Officer Comp: $1.28MMr. Douglas J. Devine (Age 53)Executive Advisor Comp: $800kMr. Chad M. Patterson (Age 41)Chief Commercial Officer Comp: $771.51kMr. Marc Rosenbaum (Age 51)Senior VP of Finance & Chief Accounting Officer Mr. Mark J. Day Ph.D. (Age 52)Chief Technology Officer Comp: $718.76kMr. Daniel G. Wilson (Age 40)Executive VP of Corporate Development & Investor Relations Comp: $670.09kMs. Sumi Shrishrimal (Age 44)Executive VP & Chief Risk Officer More ExecutivesKey CompetitorsAxonicsNASDAQ:AXNXICU MedicalNASDAQ:ICUIGlaukosNYSE:GKOSIntegra LifeSciencesNASDAQ:IARTAlphatecNASDAQ:ATECView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 11,861 shares on 12/6/2023Ownership: 0.009%Wellington Management Group LLPBought 219,167 shares on 12/1/2023Ownership: 0.715%Banque Pictet & Cie SABought 7,881 shares on 11/27/2023Ownership: 0.121%Deutsche Bank AGBought 1,580 shares on 11/24/2023Ownership: 0.109%Polar Capital Holdings PlcSold 1,718 shares on 11/22/2023Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions IRTC Stock Analysis - Frequently Asked Questions Should I buy or sell iRhythm Technologies stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iRhythm Technologies in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IRTC shares. View IRTC analyst ratings or view top-rated stocks. What is iRhythm Technologies' stock price target for 2024? 8 equities research analysts have issued 1-year price objectives for iRhythm Technologies' stock. Their IRTC share price targets range from $100.00 to $165.00. On average, they predict the company's share price to reach $131.33 in the next twelve months. This suggests a possible upside of 51.2% from the stock's current price. View analysts price targets for IRTC or view top-rated stocks among Wall Street analysts. How have IRTC shares performed in 2023? iRhythm Technologies' stock was trading at $93.67 on January 1st, 2023. Since then, IRTC shares have decreased by 7.3% and is now trading at $86.87. View the best growth stocks for 2023 here. When is iRhythm Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our IRTC earnings forecast. How were iRhythm Technologies' earnings last quarter? iRhythm Technologies, Inc. (NASDAQ:IRTC) posted its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.24. The company had revenue of $124.60 million for the quarter, compared to the consensus estimate of $122.46 million. iRhythm Technologies had a negative trailing twelve-month return on equity of 46.35% and a negative net margin of 22.19%. What ETFs hold iRhythm Technologies' stock? ETFs with the largest weight of iRhythm Technologies (NASDAQ:IRTC) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Robotics & Automation ETF (ROBO), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), BNY Mellon Innovators ETF (BKIV) and Fidelity Disruptive Medicine ETF (FMED). What is Kevin M. King's approval rating as iRhythm Technologies' CEO? 20 employees have rated iRhythm Technologies Chief Executive Officer Kevin M. King on Glassdoor.com. Kevin M. King has an approval rating of 91% among the company's employees. This puts Kevin M. King in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of iRhythm Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other iRhythm Technologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Teladoc Health (TDOC), Trade Desk (TTD), Advanced Micro Devices (AMD), Intel (INTC), Broadcom (AVGO) and Boeing (BA). When did iRhythm Technologies IPO? (IRTC) raised $76 million in an IPO on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are iRhythm Technologies' major shareholders? iRhythm Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sands Capital Management LLC (7.67%), Artisan Partners Limited Partnership (6.40%), Mackenzie Financial Corp (4.13%), JPMorgan Chase & Co. (4.02%), Blair William & Co. IL (3.63%) and FMR LLC (2.78%). Insiders that own company stock include Daniel G Wilson, David A Vort, Douglas Devine, Kevin M King, Mark J Day, Merz Cathleen Noel Bairey, Patrick Michael Murphy and Quentin S Blackford. View institutional ownership trends. How do I buy shares of iRhythm Technologies? Shares of IRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:IRTC) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iRhythm Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.